Highest-materiality recent filing
Majority shareholder approves >20% stock issuance at discount; warrant adjustments allowed
CEO Dr. Steve N. Slilaty, holding ~86% voting power, approved issuance of >20% of outstanding shares at discount to Nasdaq min price.
Sunshine Biopharma closes $6.0M public offering with up to $12M additional warrant proceeds
Gross proceeds $6.0M from 12,000,000 units at $0.50/unit; closed May 19, 2026.
Sunshine Biopharma reports FY 2025 revenue $36.3M (+4.1% YoY), net loss $5.98M
Revenue $36.31M vs $34.87M in 2024; gross profit $12.26M up from $10.67M.
Engaged Aegis Capital on March 6, 2026 to induce exercise of outstanding warrants on best-efforts basis.
Majority shareholder approves reverse stock split up to 1-for-10 for Sunshine Biopharma
Dr. Steve N. Slilaty, holding ~96% voting power, approved by written consent a reverse split of common stock up to 1-for-10.
Sunshine Biopharma COO Dr. Abderrazzak Merzouki resigns effective immediately
Dr. Abderrazzak Merzouki resigned as COO of Sunshine Biopharma on February 5, 2026, effective immediately.
All five director nominees elected: Dr. Slilaty, Sebaaly, Kiderchah, Natan, Keller received over 130M votes for.
Sunshine Biopharma dismisses Bush & Associates, appoints M&K CPAS as auditor effective Sept 24, 2025
Dismissed Bush & Associates CPA LLC as independent auditor on Sept 24, 2025; no prior disagreements or reportable events.
Sunshine Biopharma Q1 revenue up 18% to $8.9M; net loss narrows
Revenue of $8.9 million in Q1 2025, up 18% from $7.5M in Q1 2024.
Sunshine Biopharma closes $2.46M registered direct offering of common stock and pre-funded warrants
Gross proceeds of approximately $2.46M from sale of 1,188,404 shares of common stock (or pre-funded warrants) at $2.07 per share.
Sunshine Biopharma FY2024 revenue $34.9M (+45% YoY); net loss widens to $5.1M
Revenue $34.9M in FY2024, up 45% from $24.1M in FY2023; gross profit $10.7M.
Sunshine Biopharma appoints Michel Roy as Chief Commercial Officer
Michel Roy appointed CCO effective Jan 13, 2025; initial base salary of $400,000 CAD annually.
Sunshine Biopharma annual meeting: all director nominees elected with >130M votes, auditor ratified
Dr. Steve Slilaty, Dr. Merzouki, Dr. Kiderchah, Mr. Natan, Dr. Keller each elected with over 130M votes FOR.
Sunshine Biopharma Q3 2024 revenues up 42% YoY; net loss widens 84% in quarter
Q3 2024 gross revenues $8.44M, up 42% from $5.96M in Q3 2023; YTD revenues $25.28M, up 54%.
Sunshine Biopharma enters new employment agreements with CEO, CFO, COO; CEO severance of $14M USD
CEO Dr. Slilaty: $543,753 CAD base salary, 5% or CPI annual increase, $14M USD severance for termination without cause or for good reason.
Received Nasdaq letter confirming compliance with Bid Price Rule (Listing Rule 5550(a)(2)).
Sunshine Biopharma Q2 revenue $9.3M (+67% YoY); net loss narrows 45% to $(494K)
Q2 gross revenue $9,303,067, up 67% from $5,560,865 in Q2 2023.
Sunshine Biopharma announces 1-for-20 reverse stock split, effective Aug 8
1-for-20 reverse stock split effective August 8, 2024; each share converted to one-twentieth of a share.
Majority shareholder approves up to 60-for-1 reverse stock split
Dr. Steve Slilaty, holding 84.8% voting power, approved reverse split by written consent.
Sunshine Biopharma gets Nasdaq bid-price extension to Aug 26, 2024
Received Nasdaq Hearings Panel exception until August 26, 2024 to regain minimum bid price compliance.
All Series A Warrants exercised by holders as of June 11, 2024
Series A Warrants issued on Feb 15, 2024 fully exercised as of June 11, 2024.
Nasdaq notifies Sunshine Biopharma of delisting due to warrant dilution
Nasdaq staff determined to delist SBFM under Rule 5101 citing public interest concerns over Series A warrant cashless exercise provision.
Sunshine Biopharma Q1 2024 revenue up 54% to $7.54M; net loss narrows to $1.28M
Q1 2024 revenue of $7,541,046, a 54% increase from $4,894,053 in Q1 2023.
Sunshine Biopharma appoints Bush & Associates as new auditor, eff. May 7, 2024
Bush & Associates CPA LLC engaged as independent registered public accounting firm as of May 7, 2024.
Sunshine Biopharma dismisses auditor BF Borgers after SEC permanent ban
BF Borgers CPA, PC was dismissed as independent auditor after SEC settled charges and permanently banned the firm.
On January 13, 2025, Sunshine Biopharma Inc. (the “Company”) appointed Mr. Michel Roy as the Company’s Chief Commercial Officer.
Max materiality 0.85 · Median 0.50 · Most common event other_material